THE 'ENHANCER' SNP DOES NOT EXPLAIN VARIABILITY OF CYP2D6 ACTIVITY IN VIVO.

被引：0
|
作者：
Boone, E. C. [1 ]
Staggs, V. T. [1 ]
Pearce, R. E. [1 ]
Lata, R. F. [1 ]
Gaedigk, R. [1 ]
Jaime, L. K. Montane [2 ]
Cherner, M. [3 ]
Berard, A. [4 ]
Fridley, B. L. [5 ]
Dinh, J. C. [1 ]
Miller, N. A. [1 ]
Leeder, J. [1 ]
Gaedigk, A. [1 ]
机构：
[1] Childrens Mercy Kansas City, Kansas City, MO USA
[2] Int Inst Hlth Care Profess, Boca Raton, FL USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
[4] Univ Montreal, Montreal, PQ, Canada
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-055
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [1] The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity
    Dinh, Jean C.
    Boone, Erin C.
    Staggs, Vincent S.
    Pearce, Robin E.
    Wang, Wendy Y.
    Gaedigk, Roger
    Leeder, James Steven
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (03) : 646 - 654
  • [2] FUNCTIONAL CHARACTERIZATION OF RARE CYP2D6 ALLELIC VARIANTS IN VIVO.
    Gaedigk, A.
    Twist, G. P.
    Miller, N. A.
    Farrow, E. G.
    Lowry, J. A.
    Soden, S. E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S29 - S29
  • [3] Doxepin inhibits CYP2D6 activity in vivo
    Szewczuk-Boguslawska, M
    Kiejna, A
    Beszlej, JA
    Orzechowska-Juzwenko, K
    Milejski, P
    POLISH JOURNAL OF PHARMACOLOGY, 2004, 56 (04): : 491 - 494
  • [4] The effect of TCAs on CYP2D6 activity in vivo
    Szewczuk-Boguslawska, M.
    Kiejna, A.
    Beszlej, J.
    Orzechowska-Juzwenko, K.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S251 - S251
  • [5] Variability of the dietary-derived CYP2D6 activity marker solanidine in vivo
    Mueller, J. P.
    Saromba, J.
    Ziegler, P.
    Tremmef', R.
    Rengelshausen, J.
    Schaeffeler, E.
    Just, K. S.
    Schwab, M.
    Kraus, T.
    Sting, J. C.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 : S72 - S72
  • [6] Inter-individual Variability of In Vivo CYP2D6 Activity in Different Genotypes
    Chiba, Koji
    Kato, Motohiro
    Ito, Takashi
    Suwa, Toshio
    Sugiyama, Yuichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (04) : 405 - 413
  • [7] THE CYP2D6 'ENHANCER' SNP: LONG-RANGE LINKAGE ANALYSIS AND IMPACT ON ACTIVITY IN HUMAN LIVER TISSUE
    Gaedigk, Andrea
    Boone, Erin C.
    Dinh, Jean C.
    Gaedigk, Roger
    Lata, Ryan F.
    Pearce, Robin E.
    Wang, Wendy Y.
    Miller, Neil A.
    Staggs, Vincent S.
    Leeder, J. Steven
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S80 - S81
  • [8] Functional characterization of CYP2D6 enhancer polymorphisms
    Wang, Danxin
    Papp, Audrey C.
    Sun, Xiaochun
    HUMAN MOLECULAR GENETICS, 2015, 24 (06) : 1556 - 1562
  • [9] C-1584G polymorphism is not the very SNP causing increased CYP2D6 activity of CYP2D6*41.
    Lee, S
    Jeong, H
    Yea, S
    Shin, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P67 - P67
  • [10] The identification of a novel HNF-4A SNP affecting in vitro and in vivo CYP2D6 activity.
    Yeo, C.
    Kim, K.
    Cho, D.
    Cha, E.
    Lee, S.
    Shon, J.
    Shin, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S9 - S9
12345